ScreenerHero

TLSA Tiziana Life Sciences Ltd

NAS · US · Healthcare · Biotechnology · tizianalifesciences.com
1.100USD-0.90%Mkt Cap: 139.99M $P/E: —

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap139.99M USD
Enterprise Value130.21M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-18.43M USD
Revenue/Share—
Last Price1.100 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees10
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.16
PEG—
EV/EBITDA-6.17
EV/Revenue—
P/S—
P/B—
EPS (TTM)-0.16
EPS (Forward)-0.18
52W Range
0.761522% of range2.330
52W High2.330 USD
52W Low0.7615 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-35444.23%
ROA-160.34%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.85M USD
CapEx (TTM)21.00K USD
FCF Margin—
FCF Yield-3.91%
Net Debt-3.55M USD
Net Debt/EBITDA0.17
Balance Sheet
Debt/Equity8.77
Current Ratio0.76
Quick Ratio0.72
Book Value/Sh0.00 USD
Cash/Share0.03 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split2499:1000
Split DateJul 31, 2020
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)8.016 USD
Upside (mean)+628.8%
Target Range7.018 USD – 9.015 USD
7.018+628.8% to mean9.015
# Analysts2
Ownership
Shares Out.127.26M
Float60.91M
Insiders47.65%
Institutions1.90%
Short Interest
Short Ratio2.3d
Short % Float4.77%
Short % Out.1.36%
Shares Short1.73M
Short (prev mo.)1.70M
Technical
SMA 501.008 (+9.2%)
SMA 2001.259 (-12.6%)
Beta0.44
S&P 52W Chg15.78%
Avg Vol (30d)721.89K
Avg Vol (10d)711.48K
Technical Indicators
RSI (14)55.8
MACD0.0223
MACD Signal0.0045
MACD Hist.+0.0178
BB Upper1.177 USD
BB Middle1.007 USD
BB Lower0.8358 USD
BB Width33.93%
ATR (14)0.0956 USD
Vol Ratio (20d)0.63x